SAN DIEGO, Aug. 20, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) ( www.apricusbio.com) today announced a podium presentation entitled, "Nine months treatment with alprostadil cream (Vitaros®) results in sustained improvement of erectile function in males suffering from erectile dysfunction," will take place on Tuesday, August 28, 2012, at 2:30 p.m. CT as part of the upcoming World Meeting on Sexual Medicine ("WMSM"), which will take place in Chicago, IL, on August 26-30, 2012. The presentation will discuss the results of a subpopulation analysis of an open label dose titration efficacy and safety study to support Vitaros ® at the dose of 300 mcg in 100 mg of cream. This is the second Apricus Bio abstract accepted by the WMSM for presentation at this key medical industry meeting. On August 16, 2012, Apricus Bio announced that its abstract related to Femprox®, its drug candidate in development for female sexual arousal disorder ("FSAD"), had also been accepted as a podium presentation. The Vitaros® (alprostadil 0.3% topical cream) data will be presented by Dr. Jacques Buvat, director of the Centre d'Etude et de Traitement de la Pathologie de l'Appareil Reproducteur et de la Psychosomatique (CETPARP) and a member of Apricus Bio's Vitaros® Clinical Advisory Board. Dr. Buvat is also a member of editorial boards for the International Journal of Impotence Research, Archivio Italiano Nephrologia Andrologia, Andrologie and Gynécologie Obstétrique Fertilité, chief editor of bulletins for the International Society for Sexual and Impotence Research and the French Société de Médecine de la Reproduction, president of the Association pour l'Etude et le Traitement de la Pathologie de l'Appareil Reproducteur et de la Psychomatique, and of the Association pour le Développement de l'Information et de la Recherche sur la Sexualité (ADIRS). He has written more than 300 scientific papers. About Vitaros ® Vitaros® is a topically delivered formulation of alprostadil delivered with Dodecyl 2-N, N-(dimethylamino)-propionate hydrochloride (DDAIP HCl), Apricus' proprietary NexACT® delivery technology, for the treatment of erectile dysfunction ("ED"). When absorbed through the skin, alprostadil, a vasodilator, directly boosts blood flow, thereby causing an erection.
Vitaros® differs from oral medications in two ways. First, it is applied locally, directly to the penis as a cream, instead of taken orally and absorbed systemically. This topical application helps to reduce side effects and provides men who cannot take the existing oral medications a patient-friendly alternative. Second, clinical studies have shown that patients on average had successful sexual intercourse starting 5 minutes from the allocation of the Vitaros®, compared to a reported onset time of 30 minutes, or longer, for oral medications.About Apricus Biosciences, Inc. Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that develops and markets innovative treatments that help large patient populations across numerous, high-demand therapeutic classes. The Company has four approved products and has developed a strong pipeline of multiple late-stage product opportunities. With commercial operations in both the U.S. and Europe (France), Apricus Bio generates revenues and growth from sales of its commercial products and by out-licensing, in certain territories, its pipeline products and NexACT® technology. Apricus Bio's growth strategy is to acquire, develop, and commercialize new products through strategic partnerships. The Company currently has commercial partnerships with multiple large pharmaceutical companies including Novartis, Abbot Laboratories, Sandoz, Warner Chilcott, Wockhardt, and Bracco, and co-promotes multiple products in France. Apricus Biosciences is headquartered in San Diego, CA and is publicly traded on the NASDAQ under the ticker symbol APRI. For further information on Apricus Bio, visit http://www.apricusbio.com , and for information on its subsidiary please visit http://www.nexmedusa.com . You can also receive information at http://twitter.com/apricusbio . Apricus Bio's Forward-Looking Statement Safe Harbor Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, its ability to further develop its products and product candidates, to have its products such as Vitaros® and product candidates receive patent protection and be approved by relevant regulatory authorities, to successfully commercialize such products as Vitaros® and NexACT ® product candidates and drug delivery technology and to achieve its development, commercialization and financial goals. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
CONTACT: Apricus Bio Investor Relations: David Pitts Argot Partners 212-600-1902 email@example.com